<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sixty patients with advanced <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> received 2-6 monthly treatment courses combining hyperfractionated <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (300 mg/m2 i.v. over 3 h q 12 h x 6, d 1-3) with pulsed <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> (20 mg/m2/d p.o., d 1-4, 9-12, 17-20) and once daily thalidomide at individually escalating doses (100-400 mg/d) depending on tolerability (HyperCDT) </plain></SENT>
<SENT sid="1" pm="."><plain>Responding patients were maintained on daily thalidomide and monthly <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> pulses </plain></SENT>
<SENT sid="2" pm="."><plain>Complete, partial and minor response rates were 4%, 68% and 12% respectively; overall response rate was 84% (efficacy analysis) </plain></SENT>
<SENT sid="3" pm="."><plain>Median event-free and overall survival was 11 and 19 months respectively </plain></SENT>
<SENT sid="4" pm="."><plain>During at least one treatment cycle, 67% of patients experienced grade 4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo> resulting in 17% grade 3 and 9% grade 4 infections </plain></SENT>
<SENT sid="5" pm="."><plain>Side-effects, presumably related to thalidomide, included <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (40% grade 2, 16% grade 3), <z:hpo ids='HP_0002019'>constipation</z:hpo> (17%), <z:hpo ids='HP_0000969'>oedema</z:hpo> (5%), <z:hpo ids='HP_0001662'>bradycardia</z:hpo> (5%), skin reactions (3%), cerebrovascular events (5%) and <z:e sem="disease" ids="C0149871" disease_type="Disease or Syndrome" abbrv="">deep vein thromboses</z:e> (8%) </plain></SENT>
<SENT sid="6" pm="."><plain>Thromboses were not related to known thrombophilic risk factors </plain></SENT>
<SENT sid="7" pm="."><plain>Four patients with prior <z:mp ids='MP_0009440'>myeloma</z:mp> therapy &gt; 50 months developed <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or secondary <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> 2-4 months after study entry </plain></SENT>
<SENT sid="8" pm="."><plain>HyperCDT is a highly active and reasonably well-tolerated salvage regimen in advanced or refractory <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
</text></document>